Iupac Name: | N-[(2''S'')-3-methoxy-1-[[(2''S'')-3-methoxy-1-[[(2''S'')-1-[(2''R'')-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide |
Width: | 250 |
Routes Of Administration: | Oral |
Legal Status: | Investigational drug |
Cas Number: | 935888-69-0 |
Atc Prefix: | None |
Pubchem: | 25067547 |
Iuphar Ligand: | 8739 |
Chemspiderid: | 28528375 |
Unii: | MZ37792Y8J |
Kegg: | D10318 |
Chembl: | 2103884 |
Synonyms: | O-methyl-N-(2-methyl-1,3-thiazol-5-carbonyl)-L-seryl-O-methyl-N--L-serinamide |
C: | 25 |
H: | 32 |
N: | 4 |
O: | 7 |
S: | 1 |
Smiles: | COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc2ccccc2)C(=O)[C@@]3(C)CO3 |
Stdinchi: | 1S/C25H32N4O7S/c1-15-26-11-20(37-15)24(33)29-19(13-35-4)23(32)28-18(12-34-3)22(31)27-17(21(30)25(2)14-36-25)10-16-8-6-5-7-9-16/h5-9,11,17-19H,10,12-14H2,1-4H3,(H,27,31)(H,28,32)(H,29,33)/t17-,18-,19-,25+/m0/s1 |
Stdinchikey: | SWZXEVABPLUDIO-WSZYKNRRSA-N |
Oprozomib[1] (codenamed ONX 0912 and PR-047) is an orally active second-generation proteasome inhibitor developed by Proteolix, which was acquired by Onyx Pharmaceuticals, an Amgen subsidiary, in 2009. It selectively inhibits chymotrypsin-like activity of both the constitutive proteasome (PSMB5) and immunoproteasome (LMP7).[2]
It is being investigated for the treatment of hematologic malignancies, specifically, multiple myeloma, with Phase 1b studies ongoing (as of February 16, 2016).[3] Being an epoxyketone derivative, oprozomib is structurally related to carfilzomib and has the added benefit of being orally bioavailable. Like carfilzomib, it is active against bortezomib-resistant multiple myeloma cells.[4]
Oprozomib was granted orphan drug status for the treatment of Waldenström's macroglobulinaemia and multiple myeloma in 2014.[5]